Document Detail

Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
MedLine Citation:
PMID:  15293849     Owner:  NLM     Status:  MEDLINE    
This article reviews the precautions and adverse effects associated with vesnarinone use, and the potential mechanisms responsible for these complications as well as suggested treatment strategies. Vesnarinone, a quinolinone derivative, improves the haemodynamics and quality of life in patients with congestive heart failure (CHF); however, it is associated with the adverse effects of increased sudden cardiac death and neutropenia. These adverse effects have limited the application of vesnarinone to the general population but perhaps with continued research into vesnarinone-induced neutropenia and advances in arrhythmia management, the risk/ benefit ratio of vesnarinone may become favourable. For now, the use of vesnarinone should be limited to patients with CHF who have demonstrated a poor response to other cardiac medications and devices. These patients should be closely monitored for both cardiac and non-cardiac adverse effects.
Barry D Bertolet
Related Documents :
19101049 - Pulmonary hypertension in systemic sclerosis determines cardiac autonomic dysfunction a...
7226729 - Cardiac arrhythmias and ecg abnormalities in tricyclic antidepressant overdose.
10826469 - Pulmonary embolism as a cause of cardiac arrest: presentation and outcome.
20858819 - Negative ecg-gated cardiac ct in patients with low-to-moderate risk chest pain in the e...
10211629 - Cardiac troponin elevations in chronic renal failure: prevalence and clinical significa...
908559 - Mosaic trisomy 9: two additional cases.
25429209 - Soluble receptor for advanced glycation end products in critically ill patients and its...
10403929 - Soluble cd40 in the serum of healthy donors, patients with chronic renal failure, haemo...
6695819 - Flecainide dose-response relations in stable ventricular arrhythmias.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  27 Suppl 1     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2004  
Date Detail:
Created Date:  2004-08-05     Completed Date:  2004-09-14     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  11-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Death, Sudden / prevention & control
Heart Failure / complications,  drug therapy,  prevention & control
Monitoring, Physiologic / methods*
Multicenter Studies as Topic
Neutropenia / chemically induced,  complications,  prevention & control
Quinolines / adverse effects*,  antagonists & inhibitors,  therapeutic use*
Quinolones / adverse effects,  antagonists & inhibitors,  therapeutic use
Reg. No./Substance:
0/Quinolines; 0/Quinolones; 5COW40EV8M/vesnarinone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical characteristics of vesnarinone.
Next Document:  Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse...